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MaOBJECTIVES The goal of this study was to determine the prognostic value of late gadolinium enhancement (LGE)
cardiac magnetic resonance (CMR) features in patients with pulmonary hypertension.
BACKGROUND The prognostic signiﬁcance of LGE in the clinical assessment of patients with pulmonary hypertension
remains uncertain.
METHODS Consecutive patients with suspected pulmonary hypertension seen at a specialist pulmonary hypertension
referral center who underwent right heart catheterization and CMR with LGE imaging within 48 h were identiﬁed.
Short-axis late-enhancement imaging was performed using a 3-dimensional gradient spoiled echocardiography sequence
on a 1.5-T scanner. Three groups were identiﬁed: 1) no late enhancement of the myocardium; 2) late enhancement at the
right ventricular insertion points (LGE-IP); and 3) late enhancement involving the right ventricular insertion points and
the interventricular septum (LGE-S).
RESULTS Of 194 patients, 162 had pulmonary hypertension. LGE was identiﬁed in 135 of 162 (83%) patients
with pulmonary hypertension, and 47 (29%) of patients demonstrated LGE-S. Patients with LGE-S had signiﬁcantly
higher right ventricular end-diastolic volume index (p ¼ 0.013) and lower mixed venous oxygen saturation
(p ¼ 0.045) than patients with LGE-IP alone. The presence of LGE-S (p ¼ 0.022), but not LGE-IP alone, right
ventricular end-systolic volume (p ¼ 0.045), right ventricular ejection fraction (p ¼ 0.034), mixed venous oxygen
saturation (p ¼ 0.021), mean right atrial pressure (0.027), and male sex (p ¼ 0.002) predicted mortality. At
multivariate analysis, male sex was the only signiﬁcant predictor of mortality independent of covariate predictors
(p ¼ 0.027).
CONCLUSIONS The presence of LGE at the right ventricular insertion points is suggestive of the presence of pulmonary
hypertension. LGE may also be more extensive, involving the septum; however, after multivariable analysis including
other factors associated with pulmonary hypertension, septal LGE was not associated with an increase in overall
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ABBR EV I A T I ON S
AND ACRONYMS
BSA = body surface area
CMR = cardiac magnetic
resonance
CTEPH = chronic
thromboembolic disease
LGE = late gadolinium
enhancement
LGE-IP = late gadolinium
enhancement at the right
ventricular insertion points
LGE-S = late gadolinium
enhancement at the
interventricular septum
LVEDV = left ventricular
end-diastolic volume
LVESV = left ventricular
end-systolic volume
mPAP = mean pulmonary
artery pressure
PAH = pulmonary arterial
hypertension
PVR = pulmonary vascular
resistance
RVEDM = right ventricular
end-diastolic mass
RVEDV = right ventricular
end-diastolic volume
RVEF = right ventricular
ejection fraction
RVESV = right ventricular
end-systolic volume
SV = stroke volume
VMI = ventricular mass index
WHO = World Health
Organization
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1210nonspeciﬁc nature of the symptoms of
pulmonary hypertension, there is increasing
interest in improving noninvasive appro-
aches to diagnosis. Speciﬁc treatments are
available for PAH and CTEPH where severe
elevation of pulmonary vascular resistance
(PVR) usually occurs (2). The optimal treat-
ment strategy is not clear, but there is a
general consensus that patients with more
severe disease should have intensive therapy.
Consequently, there is increasing interest
in the role of various modalities in risk
stratiﬁcation.
Right ventricular failure occurs as a result
of prolonged elevation of mPAP and PVR, and
is considered the key determinant of adverse
outcome in patients with PAH and CTEPH
(3–6). Improving our understanding of the
nature of right ventricular failure in pulmo-
nary hypertension is, therefore, of value.
Cardiac magnetic resonance (CMR) is a
noninvasive, nonionizing, and reproducible
method of assessing right ventricular mor-
phology and function (7–11). The addition of
LGE CMR allows evaluation of the health of
the myocardium through the accumulation of
gadolinium. Several patterns of myocardial
LGE have been described in ischemic and
nonischemic pathologies (12–14), and studies
have assessed LGE in patients with pulmo-
nary hypertension (5,15–18).SEE PAGE 1218The clinical signiﬁcance of LGE as a clinical
marker in the context of pulmonary hyper-tension remains uncertain. Two typical patterns of
LGE exist in pulmonary hypertension: involvement of
the right ventricular insertion points alone and LGE of
the interventricular septum and the insertion points.
The prognostic signiﬁcance of these 2 subphenotypes
and the clinical value of LGE in relation to CMR right
ventricular indexes and invasive metrics measured at
right heart catheterization remain uncertain. The aim
of this study was to evaluate the prognostic value of
LGE, CMR, and invasive hemodynamics in patients
with suspected pulmonary hypertension.
METHODS
PATIENTS. Consecutive treatment-naive patients
undergoing right heart catheterization and CMR for
suspected pulmonary hypertension were identiﬁed
at a high-volume, nationally designated pulmonary
hypertension referral center. Patients with suspectedpulmonary hypertension attending the Shefﬁeld
Pulmonary Vascular Disease Unit routinely undergo
CMR as part of their diagnostic work-up. Inclusion
criteria required the patients’ right heart catheter and
CMR imaging to be performed within 48 h. Exclusion
criteria were as per standard criteria for patients
undergoing CMR. Approval for retrospective ana-
lysis of imaging techniques was granted by the local
research ethics committee.
CMR IMAGE ACQUISITION. CMR imaging was per-
formed on a 1.5-T whole-body scanner GE HDx
(GE Healthcare, Milwaukee, Wisconsin), using an
8-channel cardiac coil. Four-chamber and short-axis
cine images were acquired using a cardiac gated
multislice balanced steady-state free precession
sequence (20 frames per cardiac cycle, slice thickness
8 mm, FOV 48, matrix 256  256, BW 125 KHz/pixel,
TR/TE 3.7/1.6 ms). A stack of images in the short-axis
plane with slice thickness of 8 mm (2-mm interslice
gap) were acquired fully covering both ventricles from
base to apex. End-systole was considered to be the
smallest cavity area. End-diastole was deﬁned as the
ﬁrst cine phase of the R-wave–triggered acquisition.
Ten minutes following gadolinium contrast injec-
tion (0.1 mmol/kg of gadolinium-DTPA; Gadovist,
Bayer, Germany), late-enhancement imaging was
performed using a 2-dimensional inversion-recovery
prepped fast gradient echocardiography sequence
(repetition time 7.1 ms, echo time 3.4 ms, slice
thickness 8 mm, FOV 45  40.5, matrix 256  224).
Effective myocardial nulling was achieved with TI,
typically ranging from 100 to 160 ms, with the
inversion-recovery sequence triggered on each R-R
interval with triggering on each heartbeat. A selective
180 inversion-recovery triggered to end-diastole was
acquired in the short axis, obtaining limited 3 to 5
slices through the ventricles. Studies were performed
with patients in the supine position with a surface
coil and with retrospective electrocardiogram gating.
IMAGE ANALYSIS. Image analysis was performed on
a GE Advantage Workstation 4.1, by a radiologist
experienced in CMR, who was blinded to the patient’s
clinical information and cardiac catheter parameters.
A second observer experienced in CMR analyzed the
LGE images blinded to the clinical data and blinded to
the ﬁrst observer’s results. The scans were deﬁned
as nondiagnostic when image quality signiﬁcantly
affected cardiac measurements or volumetric analysis
could not be accurately performed.
Right and left ventricular volumes. Endocardial surfaces
were manually traced from the stack of short-axis
cine images, using our MR workstation software
(GE Advantage Workstation ReportCard) to obtain
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1211right ventricular end-diastolic volume (RVEDV),
right ventricular end-systolic volume (RVESV), left
ventricular end-diastolic volume (LVEDV), and
left ventricular end-systolic volume (LVESV). The
RVEF was calculated as: RVEF ¼ (RVEDV  RVESV)/
RVEDV  100). Right ventricular stroke volume (SV)
was calculated: as RVEDV  RVESV. Right ventricular
volume measurements were indexed for body surface
area (BSA) where appropriate, for example, RVEDV
indexed for BSA is represented as RVEDVI. Left
ventricular ejection fraction was deﬁned as: LVEDV 
LVESV/LVEDV  100 and left ventricular SV as
LVEDV  LVESV.
Right ventricular mass and ventricular mass index. The
right ventricular epicardial and endocardial borders
on each end-diastolic short-axis slice image were
outlined. The interventricular septum was considered
as part of the left ventricle. The myocardial volume
for each slice was calculated by multiplying the area
of the right ventricular wall by the slice thickness.
The product of the sum total of the myocardial
slice volumes for each ventricle and the density of
myocardium (1.05 g/cm3) was used to estimate right
ventricular end-diastolic mass (RVEDM) (10). RVEDMFIGURE 1 Subgroups Divided According to LGE Features
Group A ¼ no late gadolinium enhancement (LGE), Group B ¼ LGE at th
septum (LGE-S).index was deﬁned as RVEDM/BSA measured in g/m2.
The left ventricular epicardial and endocardial
borders on each end-diastolic short axis slice were
outlined, left ventricular end diastolic mass was
thus derived. Ventricular mass index (VMI) was
deﬁned as RVEDM divided by left ventricular end-
diastolic mass.
Late gadolinium enhancement. Late gadolinium–
enhanced images were qualitatively assessed for
hyperintensity at the interventricular insertion points
or along the interventricular septum. The presence or
absence of delayed enhancement was also recorded.
We scored images as no LGE, LGE involving the right
ventricular insertion points (LGE-IP), and LGE
involving both the right ventricular insertion points
and the interventricular septum (LGE-S), as previ-
ously described (15) (Figure 1).
RIGHT HEART CATHETERIZATION AND CLINICAL
EVALUATION. Right heart catheterization was per-
formed using a balloon-tipped 7.5-F thermodilu-
tion catheter (Becton-Dickinson, Franklin Lakes,
New Jersey). Patients referred for the investigation
of suspected pulmonary hypertension also under-
went detailed clinical evaluation including bloode insertion points (IP), and Group C ¼ LGE at the interventricular
TABLE 1 Demographic, Invasive Hemodynamic, and CMR Indexes in Patients
With Pulmonary Hypertension, and Control Patients (mPAP <25 mm Hg)
Controls
(n ¼ 32)
Pulmonary Hypertension
(n ¼ 162) p Value
Demographics
Age, yrs 59  15 61  15 0.356
Female, % 56 59 0.943
WHO functional class, n* I (3), II (13),
III (16)
I (3), II (33),
III (112), IV (14)
0.002
Catheter measurements
mRAP, mm Hg 6  3 11  5 <0.0001
mPAP, mm Hg 19  3 46  13 <0.0001
sPAP, mm Hg 30  6 75  23 <0.0001
dPAP, mm Hg 11  3 28  10 <0.0001
PCWP, mm Hg 10  3 12  6 0.036
CI, l/min/m2 3.7  0.8 2.7  0.8 <0.0001
PVR, dyne/s/cm5 120  82 630  416 <0.0001
SvO2, % 73  6.0 63.6  8.8 <0.0001
MR indexes
RVEDVI, ml/m2 72  16 99  39 <0.0001
RVESVI, ml/m2 42  13 75  37 <0.0001
RVEF, % 40  14 26  15 <0.0001
RVSVI, ml/m2 29  13 24  16 0.108
LVEDVI, ml/m2 58  16 47  14 0.001
LVESVI, ml/m2 19  10 17  8 0.222
LVEF, % 67  11 64  12 0.294
LVSVI, ml/m2 38  11 30  11 0.001
VMI, ratio 0.25  0.1 0.80  0.4 <0.0001
LGE
Absent 29 (91) 27 (17)
LGE-IP 3 (9) 88 (54)
LGE-S 0 (0) 47 (29)
Values are mean  SD, %, n, or n (%). *Comparison of WHO functional class groups I and II versus
groups III and IV.
CI ¼ cardiac index; CMR ¼ cardiac magnetic resonance; dPAP ¼ diastolic pulmonary artery
pressure; LGE ¼ late gadolinium enhancement; LVEDVI ¼ left ventricular end-diastolic
volume index; LVEF ¼ left ventricular ejection fraction; LVESVI ¼ left ventricular end-systolic
volume index; LVSVI ¼ left ventricular stroke volume index; mPAP ¼ mean pulmonary artery
pressure; mRAP ¼ mean right atrial pressure; PCWP ¼ pulmonary capillary wedge pressure;
PVR ¼ pulmonary vascular resistance; RVEDVI ¼ right ventricular end-diastolic volume index;
RVEF ¼ right ventricular ejection fraction; RVESVI ¼ right ventricular end-systolic volume index;
sPAP ¼ systolic pulmonary artery pressure; SvO2 ¼ mixed venous oxygen saturations;
VMI ¼ ventricular mass index; WHO ¼ World Health Organization.
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1212testing, echocardiography, computed tomography
scanning, lung function testing, exercise testing,
and perfusion lung imaging as appropriate. Patients
with mPAP $ 25 mm Hg were classiﬁed as having
pulmonary hypertension, with patients with
mPAP < 25 mm Hg classiﬁed as having no pulmo-
nary hypertension. Diagnostic classiﬁcation of the
form of pulmonary hypertension was by standard
criteria following multidisciplinary assessment. PVR
was determined as follows: PVR in dynes ¼ 80 
(mPAP  pulmonary capillary wedge pressure/
cardiac output). Data are also provided for the
mixed venous oxygen saturation sampled from the
pulmonary artery.STATISTICS. Comparisons of CMR measurements
between patients with “no pulmonary hyperten-
sion” and patients with pulmonary hypertension
were analyzed using the independent Student t test
for continuous data and the chi-square for categor-
ical data. World Health Organization (WHO) func-
tional class was dichotomized into groups I and II
versus groups II and IV. The Fisher exact test was
used to determine the diagnostic strength of the
presence of LGE, and the sensitivity, speciﬁcity,
negative predictive value, positive predictive value,
and likelihood ratios were calculated. Kaplan-Meier
analysis assessed the prognostic value of LGE im-
aging in patients with pulmonary hypertension.
Groups were compared by means of the log-rank
test. The interval from completion of evaluation
with CMR and right heart catheterization until all-
cause death, transplantation, or census was regar-
ded as the overall follow-up period. The prognostic
value of LGE, CMR and right heart catheter data,
and patient age and sex were assessed using uni-
variate Cox proportional hazards regression analysis
in patients with pulmonary hypertension. Variables
signiﬁcant at p < 0.05 were entered into a multi-
variate Cox proportional hazards model. Stepwise
backwards elimination was used to determine in-
dependent prognostic signiﬁcance. To perform
and display the statistics, SPSS version 18 (SPSS,
Chicago, Illinois) and GraphPad Prism version 5.03
(GraphPad Software, San Diego, California) software
were used. A p value <0.05 was considered statis-
tically signiﬁcant.
RESULTS
A total of 198 patients with suspected pulmonary
hypertension who underwent CMR including LGE
imaging were identiﬁed. Four patients had studies
that were excluded because of suboptimal scans,
leaving 194 patients. One hundred sixty-two patients
were diagnosed with pulmonary hypertension, and 32
patients with no pulmonary hypertension. Of the
patients with pulmonary hypertension, 81 had PAH
(36 idiopathic PAH, 35 PAH-connective tissue disease,
7 PAH-congenital heart disease, 3 PAH-portal), 20 had
pulmonary hypertension because of left heart dis-
ease, 17 had pulmonary hypertension associated with
lung disease and/or hypoxemia (PH-lung), and 44 had
CTEPH.
GROUP COMPARISONS. Table 1 presents demographic,
invasive hemodynamic, and CMR indexes in patients
with pulmonary hypertension, and those with no
pulmonary hypertension. The presence of LGE was
identiﬁed in 135 of 162 (83%) patients with
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1213pulmonary hypertension, and LGE was present in 3 of
32 (9%) patients with no pulmonary hypertension.
Thus, the presence of LGE had high diagnostic accu-
racy for the detection of pulmonary hypertension, but
could not conﬁdently exclude the presence of dis-
ease, with sensitivity 83% (77% to 89%), speciﬁcity
90% (75% to 98%), positive predictive value 98%
(94% to 100%), and negative predictive value 52%
(38% to 65%). Table 2 details the demographic,
hemodynamic, and CMR indexes in individual sub-
groups of pulmonary hypertension.
Eighty-eight of 162 (54%) had LGE-IP alone, and 47
(29%) demonstrated LGE-S. Patients with LGE-S had
signiﬁcantly higher RVEDV (p ¼ 0.019) than patients
with LGE-IP alone. LVEDV and SV were signiﬁcantlyTABLE 2 Demographic, Hemodynamic, and CMR Indexes in Individual
IPAH
(n ¼ 36)
PAH-CTD
(n ¼ 35)
Demographics
Age, yrs 54  17 64  12
Female, % 58 71
WHO functional class, n
I – 1
II 7 8
III 25 24
IV 4 2
Catheter measurements
mRAP, mm Hg 10  5 8  4
mPAP, mm Hg 57  11 38  15
sPAP, mm Hg 90  18 63  27
dPAP, mm Hg 37  10 22  9
PCWP, mm Hg 10  3 10  3
CI, l/min/m2 2.4  0.7 3.0  0.7
PVR, dyne/s/cm5 855  366 464  362
SvO2, % 62  7 67  8
MRI
RVEDVI, ml/m2 121  45 82  25
RVESVI, ml/m2 85  38 55  22
RVEF, % 25  16 32  13
RVSVI, ml/m2 28  23 24  11
LVEDVI, ml/m2 42  14 46  15
LVESVI, ml/m2 15  5 14  7
LVEF, % 63  9 70  10
LVSVI, ml/m2 27  11 32  11
VMI, ratio 1.0  0.3 0.6  0.4
LGE
Absent 1 (3) 9 (26)
LGE-IP 23 (64) 18 (51)
LGE-S 12 (33) 8 (23)
Values are mean  SD, %, n, or n (%).
CTEPH ¼ chronic thromboembolic disease; IPAH ¼ idiopathic pulmonary arterial
insertion points; LGE-S ¼ late gadolinium enhancement of the interventricular sept
PH-LHD ¼ pulmonary hypertension because of left heart disease; PH-Lung ¼ pulmonary h
Table 1.lower in patients with PH when compared with con-
trols (p ¼ 0.001 and p ¼ 0.001, respectively); however,
there was no signiﬁcant difference in LVESV, LVEDV,
left ventricular ejection fraction, or LVSV between
patients with LGE-IP versus LGE-S (p ¼ 0.282 to
0.907). The mixed venous oxygen saturation of blood
sampled from the pulmonary artery was also lower in
patients with LGE-S compared with those with LGE-IP
alone (p ¼ 0.045) (Table 3). No signiﬁcant differences
in mPAP, mean right atrial pressure, PVR, cardiac
index, and VMI were identiﬁed between LGE-S and
LGE-IP groups.
SURVIVAL ANALYSIS. The median time between
baseline measurements to the end of the study was
36 months (interquartile range: 12 to 48 months);Subgroups of Pulmonary Hypertension
PH-LHD
(n ¼ 20)
PH-Lung
(n ¼ 17)
CTEPH
(n ¼ 44)
74  9 64  15 62  13
20 24 45
1 – 1
8 3 5
6 10 34
– 4 4
14  6 10  4 12  5
33  6 43  8 49  10
54  16 66  14 83  19
21  5 29  7 29  8
22  5 11  3 9  4
3.3  0.9 2.9  0.9 2.4  0.7
156  55 526  328 813  397
68  6 65  11 60  8
75  26 103  36 108  11
51  18 82  36 90  40
31  9 22  12 20  12
24  10 21  12 20  12
53  16 49  10 45  12
19  15 19  8 18  7
66  15 61  13 60  11
34  9 30  11 28  10
0.4  0.1 0.6  0.2 0.9  0.3
10 (45) 1 (6) 4 (9)
8 (36) 9 (53) 26 (59)
2 (19) 7 (41) 14 (32)
hypertension; LGE-IP ¼ late gadolinium enhancement of the right ventricular
um; PAH-CTD ¼ pulmonary arterial hypertension with connective tissue disease;
ypertension associated with lung disease and/or hypoxemia; other abbreviations as in
TABLE 3 Comparison of Demographics, Hemodynamics, and CMR Measurements
in Patients With LGE-IP and Patients With LGE-S
LGE-IP
(n ¼ 88)
LGE-S
(n ¼ 47) p Value
Demographics
Age, yrs 61  15 62  15 0.746
Female, % 55 47 0.509
WHO functional class, n I (2), II (16), III (61),
IV (8)
II (10), III (31),
IV (6)
0.613
Invasive catheter measurements
mRAP, mm Hg 11  5 12  6 0.218
mPAP, mm Hg 47  12 50  13 0.221
sPAP, mm Hg 77  22 82  22 0.239
dPAP, mm Hg 29  9 31  12 0.259
PCWP, mm Hg 11  5 10  5 0.414
CI, l/min/m2 2.6  0.8 2.6  0.8 0.769
PVR, dyne/s/cm5 667  397 761  442 0.254
SvO2, % 63.7  8.1 60.2  10.2 0.045
CMR metrics
RVEDVI, ml/m2 98  35 117  42 0.013
RVESVI, ml/m2 75  31 92  42 0.014
RVEF, % 25  13 23  14 0.537
RVSVI, ml/m2 24  17 25  19 0.641
LVEDVI, ml/m2 45  14 45  14 0.907
LVESVI, ml/m2 16  7 18  11 0.282
LVEF, % 64  11 62  14 0.376
LVSVI, ml/m2 29  11 28  11 0.535
VMI, ratio 0.9  0.4 0.8  3.3 0.411
Values are mean  SD, %, or n.
Abbreviations as in Tables 1 and 2.
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1214during the follow-up period, 39 patients with pulmo-
nary hypertension died. As shown in Figure 2, at
Kaplan-Meier analysis, patients with LGE-S had worse
outcome than those patients with LGE-IP (p ¼ 0.026).
LGE-S (p ¼ 0.022) was associated with adverse
outcome at Cox proportional hazards analysis
(Table 4), whereas the presence of LGE-IP alone was
not associated with adverse outcome (p¼0.773). RVEF
and RVESV were also signiﬁcant CMR predictors of
mortality (p ¼ 0.034 and p ¼ 0.045, respectively). VMI
was not a predictor of adverse outcome (p ¼ 0.384).
Nonsurvivors with pulmonary hypertension had
higher mean right atrial pressure (p ¼ 0.027), higher
WHO functional class (p ¼ 0.029), and lower mixed
venous oxygen saturation (p ¼ 0.021) than survivors.
Male sex was also associated with worse outcome
(p ¼ 0.002) at univariate analysis and was the only
signiﬁcant predictor of outcome at multivariate anal-
ysis (p ¼ 0.027); of particular note, LGE-S was not
predictive of mortality at multivariate analysis.
INTEROBSERVER AGREEMENT FOR LGE. There was
good interobserver agreement for grading the LGE
appearances (K ¼ 0.81).DISCUSSION
The results of this study demonstrate that the
presence of LGE-IP is a characteristic feature of
pulmonary hypertension, but the presence of LGE
in these insertion points does not forecast mor-
tality. Subsets of patients with pulmonary hyperten-
sion exhibit more extensive LGE that occurs
throughout the interventricular septum. Importantly,
after considering other factors associated with the
severity of pulmonary hypertension, the presence of
LGE-S does not forecast an additional increase in
mortality risk.
The prevalence of LGE in this study is similar to
that previously found by Blyth et al. (15) (23 of
25 patients with pulmonary hypertension) and Sanz
et al. (16) (41 of 42 patients with pulmonary hyper-
tension), supporting the hypothesis that LGE in pul-
monary hypertension is characteristic. It has recently
been suggested by Freed et al. (5) that the presence of
LGE at the right ventricular insertion points is a
feature of poor outcome in patients with pulmonary
hypertension. In our study, LGE of the right ventric-
ular insertion points alone was not associated with
adverse outcome; these patients had a similar
outcome to the pulmonary hypertension patients
without visible LGE. By contrast, patients identiﬁed
with LGE involving the interventricular septum in
addition to the insertion points had a worse outcome.
We postulate that simple enhancement at the right
ventricular insertion points is a diagnostic metric,
with clinical utility for screening for pulmonary hy-
pertension. Whereas the severity of the enhance-
ment, in particular extension of the LGE into the
interventricular septum in our study, is a feature
associated with poor outcome, we note however that
LGE of the septum was not an independent marker of
adverse outcome.
CMR measurements of RVEDV, RVEF (19), mass
(20,21), pulsatility (22–24), and ﬂow (25,26) have
proven to be of clinical value in the assessment of
patients with pulmonary hypertension, and recent
studies have identiﬁed the prognostic value of
volumetric and functional CMR measurements in the
baseline and serial assessment of patients with PAH
(3,4,27). van Wolferen et al. (4) studied the prog-
nostic value of CMR measurements in 64 patients
with idiopathic PAH. They found, a large RVEDV, low
LVEDV, and low SV to be associated adverse
outcome, and changes in these metrics at follow-up
were predictive of mortality. More recently from
the same group, van de Veerdonk et al. (3) showed
that progressive reduction in RVEF at follow-
up predicts mortality independent of pulmonary
LGE-IP 88 83 79 73 73 72 72
LGE-S 47 41 32 31 31 31 31
LGE-IP
LGE-S
Log rank test: Chi square 4.96, p = 0.026
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FIGURE 2 Kaplan-Meier Plot Analysis: Outcome Comparison for Patients With
LGE-IP Versus LGE-S
The values below signify numbers at risk at 6-month intervals. CMR ¼ cardiac magnetic
resonance; LGE-IP ¼ late gadolinium enhancement of the right ventricular insertion points;
LGE-S ¼ late gadolinium enhancement of the insertion points in addition to the septum.
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1215vascular resistance. In our study, RVEF like LGE
involving the interventricular septum predicted
mortality at univariate analysis but was not found
to be independent of sex. Shehata et al. (28)
studied LGE in pulmonary hypertension patients.
They found the mass of LGE correlated with invasive
hemodynamics, reduced RVEF, increased right ven-
tricular mass, and reduced eccentricity index (28).
We note that low LVEDV (3) and SV have previously
been identiﬁed as prognostic markers in patients
with PAH and in selected idiopathic PAH cohorts
(29); however, LVEDV, LVESV, and LVEF and
SV were not found to be signiﬁcantly predictive
in this mixed cohort of patients with pulmonary
hypertension.
Measuring the severity of LGE CMR is challenging,
Blyth et al. (15) measured the mass of late gadolinium–
enhanced myocardium, which correlated well with
right ventricular volume, mass, RVEF, and mPAP. The
authors also qualitatively assessed the severity of LGE
by dividing patients into with and without septal
enhancement, as in our study. Patients with para-
doxical septal motion evident in early diastoleTABLE 4 Demographic, Right Heart Catheter, and CMR Metrics as Predictors of Adverse Outcome Using Cox Proportional Hazards
Regression Analysis
Overall Mortality
Univariate
Hazard Ratio (95% CI) p Value
Multivariate
Hazard Ratio (95% CI) p Value
Demographics
Age, yrs 1.017 (0.993–1.042) 0.164
Sex, female % 0.334 (0.167–0.666) 0.002 0.414 (0.190–0.906) 0.027
WHO functional class 2.253 (0.795–6.387) 0.126
Invasive catheter measurements
sPAP, mm Hg 0.994 (0.980–1.008) 0.396
dPAP, mm Hg 0.998 (0.969–1.031) 0.988
mPAP, mm Hg 0.993 (0.969–1.018) 0.599
mRAP, mm Hg 1.069 (1.008–1.135) 0.027 1.060 (0.983–1.129) 0.093
PCWP, mm Hg 1.005 (0.946–1.068) 0.867
SvO2, % 0.954 (0.917–0.993) 0.021 0.987 (0.936–1.042) 0.645
CI, l.min1.m2 0.773 (0.489–1.221) 0.269
PVR, dyn.s.cm5 1.000 (1.000–1.001) 0.298
MR indexes
RVEDVI, ml/m2 1.004 (0.996–1.012) 0.367
RVESVI, ml/m2 1.009 (1.000–1.017) 0.045 0.997 (0.982–1.012) 0.686
RVEF, % 0.970 (0.944–0.999) 0.034 0.987 (0.956–1.019) 0.413
RVSVI, ml/m2 0.972 (0.942–1.003) 0.073
LVEDVI, ml/m2 0.995 (0.964–1.028) 0.995
LVESVI, ml/m2 1.013 (0.947–1.062) 0.577
LVEF, % 0.983 (0.950–1.016) 0.308
LVSVI, ml/m2 0.981 (0.940–1.026) 0.412
VMI, ratio 0.606 (0.196–1.872) 0.384
LGE present or absent 1.138 (0.474–2.728) 0.773
LGE-S 2.139 (1.115–4.103) 0.022 1.598 (0.722–3.540) 0.248
CI ¼ conﬁdence interval; other abbreviations as in Tables 1 and 2.
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1216characteristically demonstrated late septal gado-
linium enhancement, suggesting that late enhance-
ment is related to strain at interventricular insertion
points. When these 2 groups were compared, patients
with LGE-S had signiﬁcantly larger right ventricular
volume and lower mixed venous oxygen saturation
than those with LGE-IP.
MECHANISM OF LGE IN PULMONARY HYPERTENSION.
The underlying mechanism of LGE in pulmonary
hypertension is not fully understood. Myocardial
ﬁbrosis as a result of mechanical stress on the
myocardium at the right ventricular insertion points
in pulmonary hypertension is believed to be an etio-
logical factor leading to LGE. In a study by McCann
et al. (17), histology was obtained in 2 patients with
PAH who died and underwent autopsy. Fibrosis was
present at the right ventricular insertion points.
However, there was also evidence of interstitial space
expansion, which may result in accumulation of
gadolinium and resultant hyperenhancement. Un-
fortunately, no direct correlation with LGE imaging
was possible because the 2 patients did not undergo
CMR. Bradlow et al. (30) undertook a pathological
correlation of insertion-region enhancement in PAH
with LGE images in a patient who died from idio-
pathic PAH. Microscopy of myocardium from the
insertion point revealed myocardial disarray and
increased collagen and fat between ﬁber bundles, but
no evidence of replacement ﬁbrosis. The authors
suggest that LGE in PAH may not directly infer
underlying myocardial ﬁbrosis. The mechanismleading to myocardial LGE and changes in the
LGE appearance over time in patients with pulmo-
nary hypertension warrants further investigation.
Methods such as native T1 mapping, extracellular
volume imaging, and T2 mapping may allow for
quantitation of the myocardial changes in pulmo-
nary hypertension, and may better characterize the
presence and extent of changes such as edema,
ﬁbrosis, and disarray.
CONCLUSIONS
The presence of LGE of the myocardium is a common
feature of pulmonary hypertension. Characteristi-
cally, the right ventricular insertion points are
involved with frequent extension of LGE into the
interventricular septum. Whereas the presence of
LGE at the right ventricular insertion points is of
diagnostic value, the presence of LGE at the inter-
ventricular septum is associated with more right
ventricular dilation despite a similar afterload.
Importantly, however, after multivariable analyses
considering other factors associated with pulmonary
hypertension, the presence of septal LGE confers no
additional increase in mortality.
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